Submission of Investor Presentation on Q4 FY26 Financial Results.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 crore (up 5.6% YoY) with EBITDA of ₹1,801 crore (20.3% margin) and net profit of ₹921 crore (up 2% YoY). Europe drove growth with 30.2% YoY increase, while US revenue declined 13% YoY to ₹3,543 crore due to lower transient product sales. The company received 9 ANDA approvals and launched 12 products in the US market. Free cash flow was $35 million with a net cash position of $317 million after the Khandelwal Labs acquisition. CuraTeQ (biosimilars) secured multiple EMA and Health Canada approvals, with Omalizumab Phase 3 successfully completed and Denosumab filing planned for Q2 2026. TheraNym biologics CMO unit expansion continues with a new MSD partnership.
EBITDA margin contracted to 20.3% from 21.4% YoY, indicating margin pressure despite revenue growth. Strong Europe performance partially offsets US headwinds, while biosimilars and biologics CMO represent emerging growth avenues beyond the core generic pharma business.